113 related articles for article (PubMed ID: 17361125)
1. Effects of uptake and efflux transporter inhibition on erythromycin breath test results.
Frassetto LA; Poon S; Tsourounis C; Valera C; Benet LZ
Clin Pharmacol Ther; 2007 Jun; 81(6):828-32. PubMed ID: 17361125
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
Paine MF; Wagner DA; Hoffmaster KA; Watkins PB
Clin Pharmacol Ther; 2002 Nov; 72(5):524-35. PubMed ID: 12426516
[TBL] [Abstract][Full Text] [Related]
3. Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers.
Gharaibeh MN; Gillen LP; Osborne B; Schwartz JI; Waldman SA
J Clin Pharmacol; 1998 Jun; 38(6):492-5. PubMed ID: 9650537
[TBL] [Abstract][Full Text] [Related]
4. Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test.
Lemahieu WP; Maes BD; Ghoos Y; Rutgeerts P; Verbeke K; Vanrenterghem Y
Am J Physiol Gastrointest Liver Physiol; 2003 Sep; 285(3):G470-82. PubMed ID: 12909563
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the erythromycin breath test for use in cancer patients.
Rivory LP; Slaviero K; Seale JP; Hoskins JM; Boyer M; Beale PJ; Millward MJ; Bishop JF; Clarke SJ
Clin Cancer Res; 2000 Sep; 6(9):3480-5. PubMed ID: 10999732
[TBL] [Abstract][Full Text] [Related]
6. Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
Srinivas NR
J Clin Pharmacol; 2009 Dec; 49(12):1492-3. PubMed ID: 19955497
[No Abstract] [Full Text] [Related]
7. Re: Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
Rao N
J Clin Pharmacol; 2011 May; 51(5):784. PubMed ID: 20671297
[No Abstract] [Full Text] [Related]
8. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
9. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin.
Niemi M; Kivistö KT; Diczfalusy U; Bodin K; Bertilsson L; Fromm MF; Eichelbaum M
Pharmacogenet Genomics; 2006 Aug; 16(8):565-8. PubMed ID: 16847425
[TBL] [Abstract][Full Text] [Related]
10. Effect of mibefradil on CYP3A4 in vivo.
Veronese ML; Gillen LP; Dorval EP; Hauck WW; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Oct; 43(10):1091-100. PubMed ID: 14517191
[TBL] [Abstract][Full Text] [Related]
11. In vivo effect of I'm-Yunity on hepatic cytochrome P450 3A4.
Nicandro JP; Tsourounis C; Frassetto L; Guglielmo BJ
J Herb Pharmacother; 2007; 7(1):39-56. PubMed ID: 17594986
[TBL] [Abstract][Full Text] [Related]
12. Application of Individualized PBPK Modeling of Rate Data to Evaluate the Effect of Hemodialysis on Nonrenal Clearance Pathways.
Franchetti Y; Nolin TD
J Clin Pharmacol; 2021 Jun; 61(6):769-781. PubMed ID: 33459400
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay.
Lam JL; Okochi H; Huang Y; Benet LZ
Drug Metab Dispos; 2006 Aug; 34(8):1336-44. PubMed ID: 16698890
[TBL] [Abstract][Full Text] [Related]
14. Erythromycin breath test and clinical transplantation.
Watkins PB
Ther Drug Monit; 1996 Aug; 18(4):368-71. PubMed ID: 8857552
[TBL] [Abstract][Full Text] [Related]
15. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
Treiber A; Schneiter R; Häusler S; Stieger B
Drug Metab Dispos; 2007 Aug; 35(8):1400-7. PubMed ID: 17496208
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.
Michael M; Cullinane C; Hatzimihalis A; O'Kane C; Milner A; Booth R; Schlicht S; Clarke SJ; Francis P
Cancer Chemother Pharmacol; 2012 Jan; 69(1):125-35. PubMed ID: 21626050
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Ushiama H; Echizen H; Nachi S; Ohnishi A
Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
[TBL] [Abstract][Full Text] [Related]
18. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine.
Stein CM; Kinirons MT; Pincus T; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1996 Jan; 59(1):47-51. PubMed ID: 8549033
[TBL] [Abstract][Full Text] [Related]
20. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans.
Mouly S; Lown KS; Kornhauser D; Joseph JL; Fiske WD; Benedek IH; Watkins PB
Clin Pharmacol Ther; 2002 Jul; 72(1):1-9. PubMed ID: 12151999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
